NEW YORK (GenomeWeb) – Newly publicly traded cancer molecular diagnostics firm Signal Genetics today said that the New York State Department of Health has approved the Myeloma Prognostic Risk Signature test, making it available in all 50 states in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.